Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
October 18, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
October 16, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and...
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
October 13, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human...
[Latest] Global Mental Health Technology Market Size/Share Worth USD 18.9 Billion by 2032 at a 16% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
September 25, 2023 18:30 ET
|
Custom Market Insights
Austin, TX, USA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Mental Health Technology Market Size, Trends and Insights By Functionality...
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
September 08, 2023 07:00 ET
|
OKYO Pharma LTD
Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial,...
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
August 30, 2023 07:00 ET
|
OKYO Pharma LTD
Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary...
Clinical Chemistry Analyzers Market Size to Worth USD 24.8 BN by 2032
August 18, 2023 10:45 ET
|
Precedence Research
Ottawa, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The global clinical chemistry analyzers market size was valued at USD 14.63 billion in 2022. The advancement of the technologies behind clinical chemistry...
Disposable Endoscopes Market to hit USD 9.7 billion by 2032, says Global Market Insights Inc.
August 13, 2023 21:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Aug. 13, 2023 (GLOBE NEWSWIRE) -- Disposable Endoscopes Market size is expected to reach USD 9.7 billion by 2032. The industry is driven by technological advancements in the...
[Latest] Global Patient Simulator Market Size/Share Worth USD 1,421.5 Million by 2032 at a 8.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
August 01, 2023 12:30 ET
|
Custom Market Insights
Austin, TX, USA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Patient Simulator Market Size, Trends and Insights By Product Type (Adult...
New Data from Clinical Studies Further Validate HeartFlow’s All-in-One Portfolio of Precision Coronary Care Solutions
July 28, 2023 09:30 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of...